JAZZ Jazz Pharmaceuticals PLC
P/E
16.81
Forward P/E
11.04
Price/Sales
3.465
Beta
0.364
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Jazz Pharmaceuticals Ziihera Hits Survival Goal, Eyes $5 Billion Peak Sales
Jazz Pharmaceuticals reported positive results from the second interim analysis of its HERIZON-GEA-01 Phase 3 trial for Ziihera (zanidatamab). The study...
JAZZ Completes $1.25 Billion Exchangeable Senior Notes Offering and Share Repurchase
Jazz Pharmaceuticals' subsidiary, Jazz Investments I Limited, has completed a private offering of $1.25 billion in 1.875% exchangeable senior notes due 2032....
Jazz Pharmaceuticals Gains FDA Approval for Ziihera Regimens in First-Line Stomach Cancer
Jazz Pharmaceuticals announced on August 25, 2026, that the U.S. Food and Drug Administration (FDA) has approved two Ziihera® (zanidatamab-hrii) treatment...
Jazz Pharmaceuticals Secures FDA Approval for Ziihera, Eyes $1.5 Billion Peak Sales
Jazz Pharmaceuticals received FDA approval on August 25, 2026, for the expanded use of Ziihera (zanidatamab-hrii). The approval covers first-line treatment for...